History of CML - Chronic Myeloid Leukemia
In 1845, CML was first described by two pathologists, Dr. Rudolf Virchow (Berlin,Germany) and Dr. John Hughes Bennett (Edinburgh, Scotland) . In 1865, Heinrich Lissauer described the use of arsenic in patients with leukemia.
In 1959, two scientists at the University of Pennsylvania (Dr. Peter C. Nowell and Dr. David E. Hungerford) noticed that the chromosome 22 in the blood cells of many CML patients was shorter than normal. After this chromosome was nicknamed "the Philadelphia chromosome".
In 1973, Dr. Janet Rowley determined that the shortened chromosome 22, the so-called Philadelphia (Ph) chromosome, was the product of a reciprocal translocation between the long arms of chromosomes 9 and 22.
In the mid-1970s, a Seattle group reported the disappearance of the Ph chromosome in CML patients who underwent allotransplant. CML can be cured for the first time. Also, interferon-α was found to induce durable complete cytogenetic responses and long-term survival, although in only a small fraction of patients.
By the 1980s, Owen Witte, M.D., and his colleagues at the University of California, Los Angeles, were able to use genetic mapping to show that the two ends of the broken chromosomes produced a cancer-causing protein, known as Bcr-Abl.
In 1998, the tyrosine kinase inhibitors (TKI) was introduced. Clinical trials was initiated by Dr. Brian Druker. The first patient took the first dose of STI-571 (now Gleevec) in June 25, 1998 at Oregon Health Sciences University. In 2001, Gleevec (imatinib) was appoved by the Food and Drug Administration (FDA)
In 1959, two scientists at the University of Pennsylvania (Dr. Peter C. Nowell and Dr. David E. Hungerford) noticed that the chromosome 22 in the blood cells of many CML patients was shorter than normal. After this chromosome was nicknamed "the Philadelphia chromosome".
In 1973, Dr. Janet Rowley determined that the shortened chromosome 22, the so-called Philadelphia (Ph) chromosome, was the product of a reciprocal translocation between the long arms of chromosomes 9 and 22.
In the mid-1970s, a Seattle group reported the disappearance of the Ph chromosome in CML patients who underwent allotransplant. CML can be cured for the first time. Also, interferon-α was found to induce durable complete cytogenetic responses and long-term survival, although in only a small fraction of patients.
By the 1980s, Owen Witte, M.D., and his colleagues at the University of California, Los Angeles, were able to use genetic mapping to show that the two ends of the broken chromosomes produced a cancer-causing protein, known as Bcr-Abl.
In 1998, the tyrosine kinase inhibitors (TKI) was introduced. Clinical trials was initiated by Dr. Brian Druker. The first patient took the first dose of STI-571 (now Gleevec) in June 25, 1998 at Oregon Health Sciences University. In 2001, Gleevec (imatinib) was appoved by the Food and Drug Administration (FDA)
VIDEOS
Clinical trial saves leukemia patient from death (History of STI-571 1999 )
April 14, 2016, Virginia Garner
Leukemia Patient Tells of New Drug (History of STI-571 1999 )
April 12, 2016, Virginia Garner
2012 (28th) Japan Prize: Dr. Rowley / Dr. Druker / Dr. Lydon
April 24, 2012, JapanPrize
The End of Cancer is within reach
2009, Knight Cancer institute, OHSU
The first day of clinical trials for Gleevec, Bud and Yvonne by DNA Learning Center
‘’The first patient, 68-year-old Bud Romine from Tillamook, Ore., will take his first dose of the experimental drug (on Thursday, June 25, 1998, at Oregon Health Sciences University’’
Clinical trial saves leukemia patient from death (History of STI-571 1999 )
April 14, 2016, Virginia Garner
Leukemia Patient Tells of New Drug (History of STI-571 1999 )
April 12, 2016, Virginia Garner
2012 (28th) Japan Prize: Dr. Rowley / Dr. Druker / Dr. Lydon
April 24, 2012, JapanPrize
The End of Cancer is within reach
2009, Knight Cancer institute, OHSU
The first day of clinical trials for Gleevec, Bud and Yvonne by DNA Learning Center
‘’The first patient, 68-year-old Bud Romine from Tillamook, Ore., will take his first dose of the experimental drug (on Thursday, June 25, 1998, at Oregon Health Sciences University’’
ARTICLES
How Imatinib Transformed Leukemia Treatment and Cancer Research
April 11, 2018, National Cancer Institute
The survivors: How an experimental treatment saved patients and changed medicine
April 25, 2017, Stat News
Chronic myeloid leukemia: reminiscences and dreams
2016, Haematologica
A Critical History of Chronic Myeloid Leukemia
January 2, 2014, Europe PMC
A Triumph in the War Against Cancer
May 2011, Smithsonian magazine
Chronic Myeloid Leukemia: A Historical Perspective (by Dr. John Goldman)
October 2010, Science Direct
50th Anniversary of the Discovery of the Philadelphia Chromosome
September 28, 2010, Fox Chase Cancer Center
Executive Summary of a Book: Magic Cancer Bullet
May 23, 2009, Discovery Medecine
OHSU Scientists Begin Human Trials Of A Drug Aimed At The Underlying Cause Of Chronic Myelogenous Leukemia by EurekAlert
Translation of the Philadelphia chromosome into therapy for CML
December 15, 2008, Journal Blood
The history of myeloproliferative disorders: before and after Dameshek
2008, Leukemia
Chronic Myeloid Leukemia: An Historical Perspective
January 1, 2008, ASH Publications
The History Of Glivec
December 27, 2005, Medical News Today
THE BCR-ABL STORY: Bench to Bedside and Back
April 23, 2004, Annual reviews
Powerful Anti-Cancer Drug Emerges from Basic Biology
May 2001, New-York Times
The Miracle Worker
February 2001, by Nick Charles
How Imatinib Transformed Leukemia Treatment and Cancer Research
April 11, 2018, National Cancer Institute
The survivors: How an experimental treatment saved patients and changed medicine
April 25, 2017, Stat News
Chronic myeloid leukemia: reminiscences and dreams
2016, Haematologica
A Critical History of Chronic Myeloid Leukemia
January 2, 2014, Europe PMC
A Triumph in the War Against Cancer
May 2011, Smithsonian magazine
Chronic Myeloid Leukemia: A Historical Perspective (by Dr. John Goldman)
October 2010, Science Direct
50th Anniversary of the Discovery of the Philadelphia Chromosome
September 28, 2010, Fox Chase Cancer Center
Executive Summary of a Book: Magic Cancer Bullet
May 23, 2009, Discovery Medecine
OHSU Scientists Begin Human Trials Of A Drug Aimed At The Underlying Cause Of Chronic Myelogenous Leukemia by EurekAlert
Translation of the Philadelphia chromosome into therapy for CML
December 15, 2008, Journal Blood
The history of myeloproliferative disorders: before and after Dameshek
2008, Leukemia
Chronic Myeloid Leukemia: An Historical Perspective
January 1, 2008, ASH Publications
The History Of Glivec
December 27, 2005, Medical News Today
THE BCR-ABL STORY: Bench to Bedside and Back
April 23, 2004, Annual reviews
Powerful Anti-Cancer Drug Emerges from Basic Biology
May 2001, New-York Times
The Miracle Worker
February 2001, by Nick Charles
